David R. Gandara, MD has been appointed chief medical officer of the International Society for liquid biopsy, an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management.
David R. Gandara, MD has been appointed chief medical officer (CMO) of the International Society for liquid biopsy (ISLB), an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management. Gandara is professor emeritus in the Division of Hematology-Oncology, Director of Thoracic Oncology and Senior Advisor to the Director, University of California Davis comprehensive Cancer Center, where he previously served as Associate Director for Clinical Research and principal investigator for the NCI Phase II Early Therapeutics award for the California Cancer Consortium.
He is recognized for his work in cancer drug and biomarker development, focusing on translational and clinical research in thoracic malignancies and has authored over 450 publications. He has previously served as president of the International Society for Study of Lung Cancer, board of directors and treasurer of the American Society of Clinical Oncology, chair of the Lung Committee for the Southwest oncology group (SWOG) and is founding co-chair of the NCI Investigational Drug Steering Committee (IDSC). He has received numerous awards and honors including the lifetime scientific award from IASLC and the Addario Foundation team science award. Gandara will devote his time at ISLB to growth of the society and oversight of its activities and interactions with other organizations.